Filing Flows › Spero Therapeutics (SPRO) › Q4 2025 › vs Q4 2024
Spero Therapeutics (SPRO) Q4 2025 vs Q4 2024 (year over year)
Spero Therapeutics's revenue rose $26.3M (+175%) from $15.0M in Q4 2024 to $41.3M in Q4 2025. Operating margin 76.0% against -144.4% (+220.5 pts).
Spero Therapeutics, Q4 2025: revenue $41.3M (+174% year over year), operating margin 76.0%, net earnings $31.5M, operating cash flow −$8.4M. The chart draws each line against Q4 2024, the increases inside each band.
Margins
| Q4 2025 | Q4 2024 | Change | |
|---|---|---|---|
| Operating margin | 76.0% | -144.4% | +220.5 pts |
| Net margin | 76.3% | -138.8% | +215.2 pts |
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $41.3M | $15.0M | $26.3M | +175% |
| Other income, net | $376K | $547K | −$171K | -31% |
| Operating profit | $31.4M | −$21.7M | $53.1M | — |
| Costs & expenses | $9.9M | $36.8M | −$26.9M | -73% |
| Pre-tax earnings | $31.8M | −$21.2M | $53.0M | — |
| Research & development | $5.6M | $28.8M | −$23.2M | -81% |
| General & admin | $4.3M | $7.1M | −$2.8M | -39% |
| Net earnings | $31.5M | −$20.9M | $52.4M | — |
| Income tax | $261K | −$290K | $551K | — |
| Operating cash sources | $40.9M | $4.0M | $36.9M | +918% |
| Share-based compensation | $1.0M | $1.5M | −$496K | -33% |
| Cash used in operations | $8.4M | $23.4M | −$15.1M | -64% |
| Working capital & other | $40.9M | $4.0M | $36.9M | +918% |
Questions
How much did Spero Therapeutics's revenue grow year over year in Q4 2025?
Spero Therapeutics's revenue rose $26.3M (+175%) from $15.0M in Q4 2024 to $41.3M in Q4 2025. Operating margin 76.0% against -144.4% (+220.5 pts).